Jan Cerny to fms-Like Tyrosine Kinase 3
This is a "connection" page, showing publications Jan Cerny has written about fms-Like Tyrosine Kinase 3.
Connection Strength
0.332
-
Kennedy A, Patel S, Ramanathan M, Gerber J, Cerny J. Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center. Ann Hematol. 2024 Mar; 103(3):1031-1033.
Score: 0.216
-
Cerny J, Yu H, Ramanathan M, Raffel GD, Walsh WV, Fortier N, Shanahan L, O'Rourke E, Bednarik J, Barton B, Kroll-Desrosiers A, Hao S, Woda B, Hutchinson L, Evens AM, Rosmarin AG, Nath R. Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). Br J Haematol. 2013 Jan; 160(2):262-6.
Score: 0.100
-
Wang SA, Galili N, Cerny J, Sechman E, Chen SS, Loew J, Liu Q, Fadare O, Hasserjian R, Jones D, Qawi H, Woda B, Raza A. Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. Am J Clin Pathol. 2006 Nov; 126(5):789-97.
Score: 0.016